Medical writer: Tim Donald, ELS
Maintenance therapy with olaparib prolonged progression-free survival (PFS) of metastatic pancreatic cancer (MPC) with a germline BRCA mutation in the randomized, phase III POLO trial. Olaparib, which was administered following first-line treatment with platinum-based chemotherapy, was well tolerated, and health-related quality of life (HRQOL) was preserved compared with placebo. Hedy L. Kindler, MD, FASCO, of The University of Chicago, presented these results (Abstract LBA4) during the June 2 Plenary Session.
âOur results are the first from a phase III trial to validate a targeted treatment in a biomarker-selected population of patients with pancreatic cancer, highlighting the importance of germline BRCA mutation testing in this setting,â Dr. Kindler said. âWe conclude that a strategic approach of first-line platinum-based chemotherapy followed by olaparib treatment should become a new standard of care for patients with MPC who have a germline BRCA mutation.â
No targeted treatment for MPC in a biomarker-selected population has been validated in a phase III trial, Dr. Kindler noted. Approximately 4% to 7% of patients with MPC have a BRCA1 and/or BRCA2 mutation.
âThis is a huge step forward for patients with MPC,â ASCO Expert Suzanne Cole, MD, of The University of Texas Southwestern Medical Centre, said during a press briefing earlier in the day. âThis is the first time that a targeted medication has been successful at stopping the growth of MPC in people who carry the BRCA mutation. More patients with MPC who also have a BRCA mutation saw their disease go dormant when they received olaparib.â Dr. Cole further noted that âat 2 years, 20% of patients were still alive, with excellent disease control, because they were taking olaparib.â
Dr. Cole said âit is now our dutyâ to search for this mutation in all patients with MPC, in order to identify those who can benefit from treatment with this oral agent.
The international, double-blind POLO trial enrolled patients with a germline BRCA mutation and metastatic pancreatic adenocarcinoma who had received 16 weeks or more of first-line platinum-based chemotherapy without progression. Of 3,315 patients screened for the study, 247 (7.5%) were identified to have a germline BRCA mutation. Of those, 154 patients were randomly assigned 3:2 to receive maintenance oral olaparib (300 mg twice daily; 92 patients assigned, 90 treated) or placebo (62 patients assigned, 61 treated). Maintenance was continued until disease progression or unacceptable toxicity. Patient characteristics were well balanced between arms.
The primary endpoint was PFS by blinded independent central review using modified RECIST version 1.1 criteria. Secondary endpoints included time to second progression, objective response rate, HRQOL, safety and tolerability, and overall survival (OS).
With 104 events recorded, PFS was significantly improved with olaparib compared with placebo (HR 0.53, 95% CI [0.35, 0.82]; P = 0.0038) with a median of 7.4 months in the olaparib arm and 3.8 months in the placebo arm.
âThis represents a 47% decrease in the risk of progression or death,â Dr. Kindler said.
At the data cut off of January 15, 2019, 30 patients receiving olaparib (32.6%) and 12 patients receiving placebo (19.4%) were progression-free. From 6 months onward, more than twice as many patients in the olaparib arm progression-free, compared with the placebo arm, Dr. Kindler said.
At the interim OS analysis, the median OS was 18.9 months in the olaparib arm and 18.1 months in the placebo arm (HR 0.91, 95% CI [0.56, 1.46]; P = 0.68). The OS data were at 46% maturity, with the final OS analysis planned at 106 events.
Objective response was seen in 23.1% of patients in the olaparib arm and 11.5% in the placebo arm. Two patients in the olaparib arm had a complete response, both of which were ongoing at data cut off, Dr. Kindler said.
âWhat is truly remarkable is that the median duration of response to olaparib in these patients who had MPC was more than 2 years,â she said. Specifically, median duration of response was 24.9 months in the olaparib arm and 3.7 months in the placebo arm.
The effect size for the primary endpoint of PFS in the trial was âimpressive,â Dr. Messersmith said, especially in the setting of pancreatic cancer. Side effects in the study were manageable, especially compared to those with cytotoxic agents, and adverse events were similar to those seen in other trials of PARP inhibitors.
The POLO trial accomplishes several âfirstsâ in pancreatic cancer, he said. POLO is the first successful biomarker-driven trial with a germline mutation, and the first successful maintenance trial designâan approach that is rare with MPC.
One important implication of the study, Dr. Messersmith said, is that molecular testing should be standard for patients with advanced pancreatic cancer.
Posted on
Previous Article
« Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer Next Article
Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials »
« Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer Next Article
Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials »
Table of Contents: ASCO 2019
Featured articles
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Breast Cancer
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer
Melanoma
Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma
Kidney Cancer
Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours
Sarcoma
Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint
Gastrointestinal Cancers
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
Hematologic Malignancies
Daratumumab a promising treatment option for transplant-eligible multiple myeloma
Paediatric Oncology
Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours
Head and Neck Cancer
Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer
Sentinel lymph node biopsy shows promise for early oral cancer
Genitourinary Cancer - Prostate Cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Multiple Myeloma
Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma
Lung Cancer
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Overcoming the challenges of immunotherapy in nonâsmall cell lung cancer
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Lurbinectedin shows promise as second-line therapy for SCLC
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Developmental Therapeutics - Immunotherapy
IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Related Articles
October 13, 2022
UEGW 2022 Highlights Podcast
Š 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com